Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Na, Sang-Hoon | - |
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Baek, Sang Hong | - |
dc.contributor.author | Jeon, Hui-Kyung | - |
dc.contributor.author | Kang, Jin-Ho | - |
dc.contributor.author | Kim, Yoon-Nyun | - |
dc.contributor.author | Park, Chang-Gyu | - |
dc.contributor.author | Ryu, Jae-Kean | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Kim, Moo-Hyun | - |
dc.contributor.author | Hong, Taek-Jong | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Cho, Seong-Wook | - |
dc.contributor.author | Cha, Dong-Hun | - |
dc.contributor.author | Jeon, Eun-Seok | - |
dc.contributor.author | Kim, Jae-Joong | - |
dc.contributor.author | Shin, Joon-Han | - |
dc.contributor.author | Park, Sung-Ha | - |
dc.contributor.author | Lee, Seung-Hwan | - |
dc.contributor.author | John, Sung-Hee | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Kim, Nam-Ho | - |
dc.contributor.author | Lee, Sung-Yun | - |
dc.contributor.author | Kwan, Jun | - |
dc.contributor.author | Jeong, Myung-Ho | - |
dc.contributor.author | Kim, Sang-Wook | - |
dc.contributor.author | Jeong, Jin-Ok | - |
dc.contributor.author | Kim, Dong-Woon | - |
dc.contributor.author | Lee, Nam-Ho | - |
dc.contributor.author | Park, Woo-Jung | - |
dc.contributor.author | Ahn, Jeong-Cheon | - |
dc.contributor.author | Won, Kyung-Heon | - |
dc.contributor.author | Lee, Seung Uk | - |
dc.contributor.author | Cho, Jang-Hyun | - |
dc.contributor.author | Kim, Soon-Kil | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Hong, Sukkeun | - |
dc.contributor.author | Yoo, Sang-Yong | - |
dc.contributor.author | Kim, Song-Yi | - |
dc.contributor.author | Kim, Byung-Soo | - |
dc.contributor.author | Juhn, Jae-Hyeon | - |
dc.contributor.author | Kim, Sun-Young | - |
dc.contributor.author | Lee, Yu-Jeong | - |
dc.contributor.author | Oh, Byung-Hee | - |
dc.date.available | 2020-02-28T08:44:38Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-08 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10276 | - |
dc.description.abstract | Purpose: The objective of this study was to evaluate the efficacy and safety of the lercanidipine/valsartan combination compared with lercanidipine monotherapy in patients with hypertension. Methods: Part 1 of this study was the randomized, multicenter, double-blind, parallel group, Phase III, 8-week clinical trial to compare superiority of lercanidipine 10 mg/valsartan 80 mg (L10/V80) and lercanidipine 10 mg/valsartan 160 mg (L10/V160) combinations with lercanidipine 10 mg (L10) monotherapy. At screening, hypertensive patients, whose diastolic blood pressure (DBP) was >90 mm Hg after 4 weeks with L10, were randomized to 3 groups of L10, L10/V80, and L10/V160. The primary end point was the change in the mean sitting DBP from baseline (week 0) after 8 weeks of therapy. Patients who were randomly assigned to L10/V160 and whose mean DBP was still >= 90 mm Hg in part 1 were enrolled to the up-titration extension study with lercanidipine 20 mg/ valsartan 160 mg (L20/V160) (part 2). Findings: Of 772 patients screened, 497 were randomized to 3 groups (166 in the L10 group, 168 in the L10/V80 group, and 163 in the L10/V160 group). Mean (SD) age was 55 (9.9) years, and male patients comprised 69%. The mean (SD) baseline systolic blood pressure (SBP)/DBP were 148.4 (15.1)/194.3 (9.5) mm Hg. No significant differences were found between groups in baseline characteristics except the percentages of previous history of antihypertensive medication. The primary end points, the changes of mean (SD) DBP at week 8 from the baseline were -2.0 (8.8) mm Hg in the L10 group, -6.7 (8.5) mm Hg in L10/V80 group, and -8.1 (8.4) mm Hg in L10/V160 group. The adjusted mean difference between the combination groups and the L10 monotherapy group was -4.6 mm Hg (95% CI, -6.5 to -2.6; P < 0.001) in the L10/V80 group and -5.9 mm Hg (95% CI, -7.9 to -4.0, P < 0.001) in the L10/ V160 group, which had significantly greater efficacy in BP lowering. A total of 74 patients were enrolled in the part 2 extension study. Changes of mean (SD) DBP and SBP from week 8 to week 12 and week 16 were -5.6 (7.9)/-8.0 (12.0) mm Hg and -5.5 (7.0)/-8.5 (11.3) nun Hg, respectively. For evaluation of the safety profile, the frequencies of adverse events between groups were also not significantly different. The most frequently reported adverse events were headache (6 cases, 20.7%) in the L10 group, dizziness (8 cases, 16.3%) in L10/V80 group, and nasopharyngitis (3 cases, 9.4%) in L10/V160 group, and the incidences of adverse events were not different between groups. (C) 2015 Elsevier HS Journals, Inc. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | CARDIOVASCULAR EVENTS | - |
dc.subject | AMLODIPINE | - |
dc.subject | VALSARTAN | - |
dc.subject | OUTCOMES | - |
dc.subject | TOLERABILITY | - |
dc.subject | METAANALYSIS | - |
dc.subject | PREVENTION | - |
dc.subject | MANAGEMENT | - |
dc.subject | MORTALITY | - |
dc.title | Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000361644600014 | - |
dc.identifier.doi | 10.1016/j.clinthera.2015.05.512 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.37, no.8, pp.1726 - 1739 | - |
dc.identifier.scopusid | 2-s2.0-84940718841 | - |
dc.citation.endPage | 1739 | - |
dc.citation.startPage | 1726 | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 37 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Ahn, Taehoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | lercanidipine | - |
dc.subject.keywordAuthor | valsartan | - |
dc.subject.keywordAuthor | combination | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | CARDIOVASCULAR EVENTS | - |
dc.subject.keywordPlus | AMLODIPINE | - |
dc.subject.keywordPlus | VALSARTAN | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.